期刊文献+

慢性肾衰竭合并冠心病患者血浆氧化型低密度脂蛋白水平变化及临床意义 被引量:1

The plasma ox-LDL levels in patients with chronic renal failure and coronary heart disease
下载PDF
导出
摘要 目的探讨慢性肾衰竭(CRF)合并冠心病患者血浆氧化型低密度脂蛋白(ox-LDL)水平变化及临床意义。方法用ELISA方法测定299例住院病人和111例健康自愿者血浆ox-LDL水平,同时测定血浆TC、TG、HDL-C、LDL-C、Scr与ALB指标。结果血浆ox-LDL水平:CRF合并冠心病组〔n=148,(430.88±190.56)μg/dl〕明显高于非合并冠心病组〔n=72,(139.13±50.15)μg/dl〕(P<0.05);CRF合并不稳定性心绞痛组〔n=66,(545.58±202.89)μg/dl〕明显高于合并稳定性心绞痛组〔n=82,(255.75±112.3)μg/dl〕(P<0.05)。CRF组〔n=220,(372.18±153.68)μg/dl〕明显高于正常对照组〔n=111,(34.90±17.65)μg/dl〕与慢性肾炎组〔n=79,(40.64±20.20)μg/dl〕(P<0.05);但慢性肾炎组与正常对照组无显著性差异(P>0.05)。结论CRF患者血浆ox-LDL水平显著高于正常人及慢性肾炎患者,并发冠心病的患者其血浆ox-LDL水平升高更为明显,其中合并不稳定性心绞痛患者血浆ox-LDL水平尤其高。因此,CRF患者血浆ox-LDL浓度的高低可间接提示动脉粥样硬化的存在及严重程度。 Objective To investigate the plasma levels of oxidized low density lipoprotein (ox-LDL) in patients with chronic renal failure(CRF) and coronary heart disease. Methods 299 patients and 111 healthy subjects were taken venous plasma after fasting for 12 h and vegetable diet for one day. The levels of ox-LDL were measured by sandwich ELISA. Results The plasma levels of ox-LDL were significantly elevated in CRF patients [ ( 372. 18 ± 135. 68 ) μg/dl , n = 220 ] compared with those of control subjects [ ( 34. 90 ± 17.65 ) μg,/dl , n = 111 ] and chronic glomerulonenephritis patients [ (40.64 ± 20. 20 ) μg/dl, n = 79 ] ( P 〈 0.05 ) . The levels of ox-LDL of CRF patients with coronary heart disease (CHD) [ n = 148, (430. 88 ± 190. 56) μg/dl] were more than those of CRF patients without CHD[ n = 72, ( 139. 13 ± 50. 15 ) μg/dl ] ( P 〈 0. 05 ). And then, the levels of ox-LDL in CRF patients with unstable angina pectoris [ n = 82, (545.58 ± 202. 89) μg/dl] were significantly higher than those of CRF patients with stable angina pectoris [n =66, (255.75 ± 112. 38) μg/dl) (P 〈 0.05) ]. Conclusions The elevated level of plasma ox-LDL in CRF patients may result in artherosclerosis disease.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2009年第24期3169-3172,共4页 Chinese Journal of Gerontology
关键词 氧化型低密度脂蛋白 慢性肾衰竭 冠心病 Oxidized low density lipoprotein Chronic renal failure Coronary heart disease
  • 相关文献

参考文献15

  • 1Foley RN, Parfrey PS, Sarnak MJ ,et al. Cardiovascular disease in chronic renal disease[ J]. Am J kidney Dis, 1998 ;32 ( suppl 3 ) : 112-9.
  • 2Holvoet P, Jenny NS, Schreiner PJ, et al. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis ( MESA) [ J]. Atherosclerosis ,2007 ; 194 ( 1 ) :245-52.
  • 3Stephens JW, Gable DR, Hurel S J, et al. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males [J]. Clin Chem,2006;52(3):446-52.
  • 4Kasahara J, Kobayashi K, Maeshima Y, et al. Clinical significance of serum oxidized low-density lipoprotein/beta2-glycoprotein I complexes in patients with chronic renal diseases [ J ). Nephron Clin Pract, 2004 ; 98 ( 1 ) :c15-24.
  • 5Lee HS, Kim YS. Identification of oxidized low density lipoprotein in human renal biopsies[ J]. Kidney Int, 1998 ;54 (3) :848-56.
  • 6Magil AB, Frohlich JJ, Innis SM ,et al. Oxidized low density lipoprotein in experimental focal glomerulosclerosis [ J ]. Kidney Int, 1993 ;43 ( 6 ) : 1243- 50.
  • 7Zwolinska D,Grzeszczak W,Szczepanska M,et al. Vitamins A,E and C as non-enzymatic antioxidants and their relation to lipid peroxidation in children with chronic renal failure [ J]. Nephron Clin Pract, 2006 ; 103 ( 1 ) : 12-8.
  • 8Sener G, Sakarcan A, Sehirli O ,et al. Chronic renal failure-induced multi- pie-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast [J]. Prostaglandins Other Lipid Mediat, 2007 ; 83 (4) :257-67.
  • 9Droeke TB, Khoa TN, Massy ZA, et al. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia[ J]. Kidney Int, 2001;59 (suppl 78) :114-9.
  • 10张岩.高血脂所致肾脏损害及机理[J].国外医学(泌尿系统分册),2001,21(5):219-221. 被引量:7

二级参考文献29

  • 1Grone HJ.Am J Physiol Renal Physiol,2000;278:F63-74
  • 2Dominguez JH,Tang N,Xu W,et al.Kidney Int,2000;57:92-104
  • 3Galle J,Heinloth A,Schwedler S,et al.Kidney Int,1997;51:253-260
  • 4Grone HJ,Walli A,Grone E,et al.Lab Invest,1989;60:433-445
  • 5Atarashi K,Takagi M,Minami M,et al.J Hypertens,1999;17:1983-1986
  • 6Oda H,Keane WF.Kidney Int Suppl,1999;71:S2-S5
  • 7Hattori M,Ito K,Kawaguchi H,et al.Nephron,1994;67:459-468
  • 8Kasiske BL,O'Donnell MP,KIM Y,et al.Kidney Int,1994;45:S51~S53
  • 9O'Donnell MP,Kasiske BL,KIM Y,et al.J Clin Invest,1993;91:83-87
  • 10Nakayama K,Hara T,Kusunoki M,et al.Metabolism,2000;49:588-593

共引文献42

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部